Dave Nichols had an active research program at Purdue University for 38 years prior to his retirement in June 2012. His research interests focused in two areas: the study of hallucinogens (psychedelics), where he was recognized as an international authority, and also discovery of novel D1 dopamine receptor full agonists, which showed efficacy comparable to levodopa in both animal models of Parkinson’s disease, and in human Parkinson patients. One of his D1 agonists is currently in clinical trials in schizophrenia patients to determine whether a D1 agonist can improve working memory and cognition. His general interests continue in the medicinal chemistry and pharmacology of CNS-active agents.
David Nichols, Ph.D.